Staged Diabetes Management: A Systematic Approach, Second Edition

Staged Diabetes Management: A Systematic Approach, Second Edition

Volumn , Issue , 2006, Pages 1-434

  Mazze, Roger S ^a   Strock, Ellie S ^a   Simonson, Gregg D ^a   Bergenstal, Richard M ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84890307166     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470061701     Document Type: Book

References (273)

1. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
2. Ohkubo Y, Kishikawa H and Araki E. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-117.
3. Meigs JB, Singer DE, Sullivan LM, et al. Metabolic control and prevalent cardiovascular disease in non-insulin-dependent diabetes mellitus (NIDDM): the NIDDM patient outcomes research team. Am J Med 1997; 102: 38-47.
4. Turner RC, Millns H, Neil HA, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). Br Med J 1998; 316: 823-828.
5. Rith-Najarian S, Branchaud C, Beaulieu O, Gohdes D, Simonson G and Mazze R. Reducing lower extremity amputation due to diabetes: application of the Staged Diabetes Management approach in a primary care setting. J Fam Pract 1998; 47: 127-132.
6. Mazze RS, Etzwiler DD, Strock ES, et al. Staged Diabetes Management: toward an integrated model of diabetes care. Diabetes Care 1994; 17: 56-66.
7. United Kingdom Prospective Diabetes Study Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
8. Institute of Medicine. Clinical Practice Guidelines. Field MJ and Lohr KN, eds. Washington, DC: National Academy Press, 1990.
9. Nathan DM. Inferences and implications: do results from the Diabetes Control and Complications Trial apply in NIDDM? Diabetes Care 1995; 18(2): 251-257.
10. Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. Epidemiology of Diabetes Interventions and Complications (EDIC): design and implementation of a longterm follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care 1999; 22: 99-111.
11. Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med 2000; 342: 381-389.
12. Mazze RS and Simonson GS. Staged Diabetes Management: a systematic evidence-based approach to the prevention and treatment of diabetes and its co-morbidities. Proceedings of Staged Diabetes Management: Worldwide Outcomes 2000. Pract Diabetes Int Suppl 2001; 7: S1-S16.
13. United Kingdom Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
14. Ford ES, Giles WH and Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-359.
15. National Cholesterol Education Adult Treatment Panel III, NIH Publication Number 01-3305, 2001.
16. Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2000. Atlanta, GA: US Departments of Health and Human Services, Centers for Disease Control and Prevention, 2002.
17. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20: 1183-1197.
18. National Committee for Quality Assurance (NCQA) Diabetes Physician Recognition Program. 2004, www.ncqa.org/dprp.
19. Institute of Medicine. Clinical Practice Guidelines. Field MJ, Lohr KN, eds. Washington, DC: National Academy Press, 1990.
20. Mazze RS, Etzwiler DD, Strock ES, et al. Staged Diabetes Management: toward an integrated model of diabetes care. Diabetes Care 1994; 17: 56-66.
21. Barr JK, Schachter M, Rosenberg SN, et al. Procedure-specific costs and savings in a mandatory program for second opinion on surgery. Qual Rev Bull 1990; 16: 25-32.
22. Deming WE. Out of the Crisis. Massachusetts Institute of Technology, 1986.
23. Barney M and McCarty T. The New Six Sigma. Minneapolis: Pearson Higher Education. 2002.
24. Rickheim PL, Weaver TW, Flader JL and Kendall DM. Assessment of group versus individual diabetes education: a randomized study. Diabetes Care 2002; 25(2): 269-274.
25. Mazze R and Simonson G. Staged Diabetes Management: a systematic evidence-based approach to the prevention and treatment of diabetes and its comorbidities. Pract Diabetes Int 2001; 18(7) (Supplement).
26. Sidorov J, Shull R, Tomcavage J, Girolami S, Lawton N and Harris R. Does diabetes disease management save money and improve outcomes? A report of simultaneous short-term savings and quality improvement associated with a health maintenance organization-sponsored disease management program among patients fulfilling health employer data and information set criteria. Diabetes Care 2002; 25(4): 684-689.
27. Benjamin E and Bradley R. Systematic Implementation of Customized Guidelines: The Staged Diabetes Management Approach. Journal of Clinical Outcomes Management 2002; 9: 81-86.
28. Franz MJ, Monk A, Barry B, et al. Effectiveness of medical nutrition therapy provided by dietitians in the management of non-insulin dependent diabetes mellitus: a randomized, controlled clinical trial. J Am Diet Assoc 1995; 95: 1009-1017.
29. Beck-Nielsen H, Hother-Nielsen O and Pedersen O. Mechanism of action of Sulfonylureas with special reference to the extrapancreatic effect: an overview. Diabetes Med 1988; 5: 613-620.
30. Bailey CJ. Biguanides and NIDDM. Diabetes Care 1992; 15: 755-772.
31. Herman LS, Schersten B, Bitzen PO, Kjellstrom T, Lindgarde F and Melander A. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. Diabetes Care 1995; 17(2): 1100-1108.
32. Fuhlendorff J, Rorsman P, Kofod H, et al. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes 1998; 47: 345-351.
33. Inzucchi SE, Maggs DG, Spollett GR, et al. Efficacy and metabolic effects of metformin and troglitazone in type 2 diabetes mellitus. N Engl J Med 1998; 338(13): 908-909.
34. Coniff R and Krol A. Acarbose: a review of US clinical experience. Clin Ther 1997; 19(1): 16-26.
35. Howey DC, Bowsher RR, Brunelle RL and Woodworth Jr. [Lys(B28), Pro (B290]-human insulin: a rapidly absorbed analogue of human insulin. Diabetes 1994; 43: 396-402.
36. DiMarchi RD, Chance RE, Long HB, Shields JE and Slieker LJ. Preparation of an insulin with improved pharmacokinetics relative to human insulin through consideration of structural homology with insulin-like growth factor I. Horm Metab Res (Suppl. 2) 1994; 41: 93-6.
37. Mazze RS, Lucido D, Langer O, Hartmann K and Rodbard D. Ambulatory glucose profile: representation of verified self-monitored blood glucose data. Diabetes Care 1987; 10: 111-117.
38. Moses R, Slobodniuk R, Boyager S, et al. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with Type 2 diabetes. Diabetes Care 1999; 22: 119-124.
39. Glueck CJ, Wang P, Goldenberg N and Sieve-Smith L. Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. Hum Reprod 2002; 17: 2858-2864.
40. Smith U. Pioglitazone: mechanism of action. Int J Clin Pract 2001; 121: 13-18.
41. Stumvoll M and Haring HU. Glitazones: clinical effects and molecular mechanisms. Ann Med 2002; 34: 217-224.
42. Inzucchi SE et al. Efficacy and metabolic effects of metformin and troglitazone in type 2 diabetes mellitus. N Engl. J Med 338: 867-872.
43. Hallsten K, Virtanen KA, Lonnqvist F, et al. Rosiglitazone but not metformin enhances insulinand exercise stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes. Diabetes 2002; 51: 3479-3485.
44. Ovalle F and Bell DS. Clinical evidence of thiazolidinedione-induced improvement in pancreatic beta-cell function in patients with types diabetes mellitus. Diabetes Obes Metab 2002; 4: 56-59.
45. Iuorno MJ and Nestler JE. Insulin lowering drugs in polycystic ovary syndrome. Obstet Gynecol Clin North Am 2001; 28: 153-164.
46. Home PD and Ashwell SG. An overview of insulin glargine. Diabetes Metab Res Rev 2002; Suppl 3: S57-S63.
47. Koschinsky T and Heinemann L. Sensors for glucose monitoring: technical and clinical aspects. Diabetes Metab Res Rev 2001; 17: 113-123.
48. Gabriely I, Wozniak R, Mevorach M, et al. Transcutaneous glucose measurement using near infrared spectroscopy during hypoglycemia. Diabetes Care 1999; 22: 2026-2032.
49. Garg SK, Potts RO, Ackerman NR, et al. Correlation of finger stick blood glucose measurements with Glucowatch Biographer glucose results in young subjects with type 1 diabetes. Diab Care 1999; 22: 1708-1714.
50. Bode BW, Gross TM, Thorton KR, et al. Continuous glucose monitoring used to adjust diabetes therapy improves glycosylated hemoglobin: a pilot study. Diab Res Clin Pract 1999; 46: 183-190.
51. Centers for Disease Control National Center for Chronic Disease Prevention and Health Promotion. National Diabetes Fact Sheet, 2003.
52. American Diabetes Association. Diabetes 1996: Vital Statistics.
53. Youngren JF, Goldfine ID and Prately RE. Decreased muscle insulin receptor kinase correlates with insulin resistance in normoglycemic Pima Indians. Am J Physiol 1997; 273: E276-E283.
54. Sinha MK, Pories WJ, Flickinger EG, Meelheim D and Cara JF. Insulin-receptor kinase activity of adipose tissue from morbidly obese humans with and without NIDDM. Diabetes 1987; 36: 620-625.
55. Kusari J, Kenner KA, Suh KI, Hill DE and Henry RR. Skeletal muscle protein tyrosine phosphatase activity and tyrosine phosphatase 1B protein content are associated with insulin action and resistance. J Clin Invest 1994; 93: 1156-1162.
56. Boden G, Chen X, Ruiz J, White JV and Rossetti L. Mechanisms of fatty acid-induced inhibition of glucose uptake. J Clin Invest 1994; 93: 2438-2446.
57. Foley JE. Rationale and application of fatty acid oxidation inhibitors in treatment of diabetes mellitus. Diabetes Care 1992; 15: 773-784.
58. Moller DE. Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes. Trend Endocrinol Metab 2000; 11: 212-217.
59. Bertin E, Nguyen P, Guenounou M, Durlach V, Potron G and Leutenegger M. Plasma levels of tumor necrosis factor-alpha (TNF-alpha) are essentially dependent of visceral fat amount in type 2 diabetic patients. Diabetes Metab 2000; 26: 178-182.
60. Youd JM, Rattigan S and Clark MG. Acute impairment of insulin-mediated capillary recruitment and glucose uptake in rat skeletal muscle in vivo by TNF-alpha. Diabetes 2000; 49: 1904-1909.
61. Abate N. Insulin resistance and obesity. Role of fat distribution pattern. Diabetes Care 1996; 19: 292-294.
62. Leahy JL, Bonner Weir S and Weir GC. β-cell dysfunction induced by chronic hyperglycemia. Current ideas on mechanism of impaired glucoseinduced insulin secretion. Diabetes Care 1992; 15: 442-455.
63. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
64. Kuusisto J, Mykkanen L, Pyorala K and Laakso M. NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 1994; 43: 960-967.
65. Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 1995: 18: 258-268.
66. Ohkubo Y, Kishikawa H and Araki E. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-117.
67. Garg A. Treatment of diabetic dyslipidemia. Am J Cardiol 1998; 81(4A): 47B-51B.
68. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
69. Turner RC, Millns H, Neil HA, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). Br Med J 1998; 316: 823-828.
70. Harris MI. Classification, diagnostic criteria, and screening for diabetes. Diabetes in America 1995; NIH Publications No. 95-1468(2): 15-36.
71. Meigs JB, Singer DE, Sullivan LM, et al. Metabolic control and prevalent cardiovascular disease in non-insulin-dependent diabetes mellitus (NIDDM): the NIDDM patient outcome research team. Am J Med 1997; 102: 38-47.
72. Stern MP and Haffner SM. Dyslipidemia in type II diabetes: implications for therapeutic intervention. Diabetes Care 1991; 14: 1144-1159.
73. Neel JV. Diabetes mellitus: a "thrifty" genotype rendered detrimental by "progress?" Am J Hum Genet 1962; 14: 353-62.
74. Knowler WC, Barret-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
75. Uusitupa M, Louheranta A, Lindstrom J, Valle T, Sundvall J, Eriksson J and Tumomilehto J. The Finnish Diabetes Prevention Study. Br J Nutr 2000; Suppl 1: S137-142.
76. American Diabetes Association. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2003; 26: S5-S20.
77. Azen SP, Peters RK, Berkowitz K, Kjos S and Xiang A, Buchanan TA. Tripod (troglitazone in the prevention of diabetes): a randomized, placebocontrolled trial of troglitazone in women with prior gestational diabetes mellitus. Control Clin Trials 1998; 19: 217-231.
78. Nathan DM. Inferences and implications: do results from the Diabetes Control and Complications Trial apply in NIDDM? Diabetes Care 1995; 18: 251-257.
79. Mazze RS, Shamoon H, Parmentier R, et al. Reliability of blood glucose monitoring by patients with diabetes. Am J Med 1984; 77: 211-217.
80. Mazze RS. Measuring and Managing hyperglycemia in pregnancy: from glycosurin to continuous blood glucose monitoring. Seminars in Perinatology 2002; 26(3): 171-180.
81. Watts NB, Spanheimer RG, DiGirolamo M, et al. Prediction of glucose response to weight loss in patients with non-insulin-dependent diabetes mellitus. Arch Intern Med 1990; 150: 803-806.
82. Frankenfield DC, Muth ER and Rowe WA. The Harris-Benedict studies of human basal metabolism: history and limitations. J Am Diet Assoc 1998; 98: 439-445.
83. Devlin JT. Effects of exercise on insulin sensitivity in humans. Diabetes Care 1992; 15: 1690-1693.
84. Chiasson JL, Josse RG, Hunt JA, et al. The efficacy of acarbose in the treatment of patient with non-insulin-dependent diabetes mellitus. Ann. Intern Med 1994; 12: 928-935.
85. John JL, Wolf SL and Kabadi UM. Efficacy of insulin and sulfonylurea combination therapy in type II diabetes: a meta-analysis of the randomized placebo-controlled trials. Arch Intern Med 1996; 156: 259-264.
86. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
87. Prochaska JO, Norcross JC and Diclemente CC. Changing for Good. New York: Avon, 1994.
88. Kahn CR. Causes of insulin resistance. Nature 1995; 373: 384-385.
89. Reaven GM, Laws A. Insulin resistance, compensatory hyperinsulinemia, and coronary heart disease. Diabetologia 1994; 37: 948-952.
90. Wing RR, Blair EH, Bononi P, Marcus MD, Watanabe R, Bergman RM. Caloric restriction per se is a significant factor in improvements in glycemic control and insulin sensitivity during weight loss in obese NiDDM patients. Diabetes Care 1994; 17: 30-36.
91. Klein R, Klein BEK and Moss S. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: a review. Diabetes Metab Rev 1989; 5: 559-570.
92. Nathan DM, Singer DE, Hurxthal K and Goodson JD. The clinical information value of the glycosylated hemoglobin assay. N Engl J Med 1984; 310: 341-346.
93. Monk A, Barry B, McClain K, Weaver T, Cooper N and Franz M. Practice guidelines for medical nutrition therapy provided by dietitians for persons with non-insulin dependent diabetes mellitus. J Am Diet Assoc 1995; 95: 999-1006.
94. Franz, MJ, Monk A, Barry B, et al. Effectiveness of medical nutrition therapy provided by dietitians in the management of non-insulin dependent diabetes mellitus; A randomized, controlled clinical trial. J Am Diet Assoc 1995; 95: 1009-1017.
95. Jensen-Urstad KJ, Reichard PG, Rosfors S and Lindblad LEL, Jensen-Urstad MT. Early atherosclerosis is retarded by improved long-term blood glucose control in patients with DDM. Diabetes 1996; 45: 1253-1258.
96. Bailey CJ, Path MRC and Turner RC. Metformin. N Engl J Med 1996; 334: 574-579.
97. Kaufman FR. Type 2 diabetes mellitus in children and youth: a new epidemic. J Pediatr Endocrinol Metab 2002; Suppl 2: 737-744.
98. Fagot-Campagna A. Emergence of type 2 diabetes mellitus in children: epidemiological evidence. J Pediatr Endocrinol Metab 2000; Suppl 6: 1395-1402.
99. American Diabetes Association (ADA). Type 2 Diabetes in Children and Adolescents. Pediatrics 2000; 105: 671-680.
100. LeRoith D. Beta-cell dysfunction and insulin resistance in type 2 diabetes: role of metabolic and genetic abnormalities. Am JMed 2002; 113: 3S-11S.
101. Neel, JV. Diabetes mellitus: a 'thrifty' geno-type rendered detrimental by 'progress?' Am J Hum Genet 1962; 14: 353-362.
102. Klein R, Klein BEK, Moss SE and Cruickshanks KJ. Relationship of hyperglycemia to the longterm incidence and progression of diabetic retinopathy Arch Intern Med 1994; 154: 2169-2178.
103. Sothern MS. Trim Kids Harper Resource. 2001.
104. American Diabetes Association (ADA). Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2003; 26: S5-S20.
105. Nathan DM, Singer DE, Hurxthal K and Goodson JD. The clinical information value of the glycosylated hemoglobin assay. N Engl J Med 1984; 310: 341-346.
106. Mazze RS, Shamoon H, Parmentier R, et al. Reliability of blood glucose monitoring by patients with diabetes. Am J Med 1984; 77: 211-217.
107. Mazze RS. Computers and diabetes therapy; key variables and quality of data for clinical decision making. Horm Metab Res Suppl 1990; 24: 97-102.
108. Kaufman FR. Effect of metformin in children with type 2 diabetes. Curr Diab Rep 2001; 1: 9-10.
109. Jones KL, Arslanian S, Peterokova VA, Park JS and Tomlinson MJ. Effect of metformin in pediatric patients with type 2 diabetes: a randomized controlled trial. Diabetes Care 2002; 25: 89-94.
110. Soergel M and Schaefer F. Effect of hypertension on the progression of chronic renal failure in children. Am J Hypertens 2002; 15: 53S-56S.
111. American Diabetes Association Consensus Statement. Management of dyslipidemia in children and adolescents with diabetes. Diabetes Care 2003; 26: 2194-2197.
112. Yki-Ja "rvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care 2001; 24: 758-767.
113. National Institute of Diabetes and Digestive and Kidney Diseases (National Diabetes Information Clearinghouse). Diabetes Statistics 1997; 98-3926.
114. International Diabetes Federation. Diabetes Atlas 2000.
115. Palmer JR and Lernmark A. Pathophysiology of type 1 (insulin-dependent) diabetes. In: Porte D and Sherwin RS, eds. Ellenberg and Rifkins Diabetes Mellitus, 5th ed. Stamford, CT: Appleton and Lange, 1997.
116. Olmos P, A'Hern R and Heaton DA. The significance of concordance rate for type 1 (insulindependent) diabetes in identical twins. Diabetologia 1988; 31: 747-750.
117. Sanjeevi CB, Lybrand TP, Landin-Olsson M, et al. Analysis of antibody markers, DRB1, DRB5, DQA1 and DQB1 genes and modeling of DR2 molecules in DR2-positive patients with insulindependent diabetes mellitus. Tissue Antigens 1994; 44: 110-119.
118. Bottazzo GF, Florin-Christensen A and Doniach D. Islet cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet 1974; 2: 1279-1283.
119. Myers MA, Rabin DU and Rowley MJ. Pancreatic islet cell cytoplasmic antibody in diabetes is represented by antibodies to islet cell antigen 512 and glutamic acid decarboxylase. Diabetes 1995; 44: 1290-1295.
120. Karounos DG, Wolinsky JS and Thomas JW. Monoclonal antibody to rubella virus capsid protein recognizes a beta-cell antigen. J Immunol 1993; 150: 3080-3085.
121. Pozzilli P. The DPT-1 trail: a negative result with lessons for future type 1 diabetes prevention. Diabetes Metab Res Rev 2002 18: 257-259.
122. Libman I, Songer T and LaPorte R. How many people in the U.S. have IDDM? Diabetes Care 1993; 16: 841-842.
123. Dokheel TM. An epidemic of childhood diabetes in the United States? Evidence from the Allegheny County, Pennsylvania, Pittsburgh Diabetes Epidemiology Research Group. Diabetes Care 1993; 16: 1606-1611.
124. Dorman JS, McCarthy BJ, O'Leary LA and Koehler AN. Risk factors for insulin dependent diabetes. Diabetes America 1995; 96-1468(2): 166-177.
125. Zimmet P, Turner R, McCarty D, Rowley M and MacKay I. Crucial points at diagnosis. Diabetes Care 1999; 22: B59-B64.
126. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
127. Mazze R, Shamoon H, Parmentier R, et al. Reliability of blood glucose monitoring by patients with diabetes. Am J Med 1984; 77: 211-217.
128. Prochaska JO, Norcross JC and Diclemente CC. Changing for Good. New York: Avon, 1994.
129. Buchanan TA. Pregnancy in preexisting diabetes. In: Diabetes in America 2nd Ed, 1995: 719-733.
130. Benjamin E, Winters D, Mayfield J and Gohdes D. Diabetes in pregnancy in Zuni Indian women. Diabetes Care 1993; 16: 1231-1235.
131. Coustan DR. Gestational diabetes. In: Diabetes in America 2nd Ed, 1995: 703-717.
132. O'Sullivan J and Mahan C. Criteria for the oral glucose tolerance test in pregnancy. Diabetes 1964; 13: 278-285.
133. Mestman JH. Follow-up studies in women with gestational diabetes. In: Weiss P, Coustan D, eds. Gestational Diabetes. Vienna: Springer, 1988: 191.
134. O'Sullivan J and Mahan C. Diabetes subsequent to the birth of a large baby: a 16-year prospective study. J Chronic Dis 1980; 33: 37-45.
135. Persson B, Edwall L, Hanson U, Nord E and Westgren M. Insulin sensitivity and insulin response in women with gestational diabetes mellitus. Horm Metab Res 1997; 29(8): 393-397.
136. Kuhl C. Etiology and pathogenesis of gestational diabetes. Diabetes Care 1998; 21 (Suppl 2): B19-B26.
137. Goldenberg RL and Rouse DJ. Prevention of premature birth. N Engl J Med 1998; 339: 313-320.
138. Peterson A, Peterson K, Mazze R et al. Glucose intolerance as a consequence of oral terbutaline treatment for preterm labor. J Fam Pract 1993; 36: 25-31.
139. Mello G, Parretti E, Mecacci F et al. Glycemic thresholds in spontaneous abortion during the first trimester in pregnant women with insulin dependent diabetes. Minerva Ginecol 1997; 49: 354-370.
140. Mironiuk M, Kietlinska Z, Jezierska-Kasprzyk K and Piekosz-Orzechowska B. A class of diabetes in mother, glycemic control in early pregnancy and occurrence of congenital malformations in newborn infants. Clin Exp Obstet Gynecol 1997; 24: 193-197.
141. Weintrob N, Karp M and Hod M. Short-and longrange complications in offspring of diabetic mothers. J Diabetes Complications 1996; 10: 294-301.
142. Langer O, Anyaegbunam A, Brustman L, Guidetti D, Levy J and Mazze R. Pregestational diabetes: insulin requirements throughout pregnancy. Am J Obstet Gynecol 1988; 159: 616-621.
143. Piper JM, Field NT, Higby K, Elliot BD and Langer O. Maternal-fetal glucose metabolism and fetal growth retardation: is there an association? J Reprod Med 1996; 41: 761-766.
144. Langer O. When diets fail: insulin and oral hypoglycemic agent as alternatives for the management of gestational diabetes mellitus. J Matern Fetal Neonatal Med 2002; 11: 218-225.
145. O'Sullivan J, Mahan C, Charles D and Dandrow RV. Screening criteria for high-risk gestational diabetic patients. Am J Obstet Gynecol 1973; 116: 895-900.
146. Langer O. Maternal glycemic criteria for insulin therapy in gestational diabetes mellitus. Diabetes Care 1998; 21 (Suppl 2): B91-B96.
147. Langer O, Conway DL, Berkus MD, Xenakis EM and Gonzales O. A comparison of glyburide and insulin in women with gestational diabetes mellitus. N Engl J Med 2000; 343: 1134-1138.
148. Jovanovic L, Ilic S, Pettitt DJ, Hugo K, Gutierrez M, Bowsher RR and Bastyr EJ. Metabolic and immunologic effects of insulin lispro in gestational diabetes. Diabetes Care 1999; 22: 1422-1427.
149. Bhattacharyya A, Brown S, Hughes S and Vice PA. Insulin lispro and regular insulin in pregnancy. QJM 2001; 94: 255-260.
150. Prochaska JO, Norcross JC and Diclemente CC. Changing for Good. New York: Avon, 1994.
151. Wingard DL and Barrett-Connor EL. Heart disease and diabetes. In Diabetes in America. 1995 NIH publication no 95-1468, pp 429-448.
152. Kannel WB. Lipids, diabetes, and coronary heart disease: insights from the Framingham Study. Am Heart J 1985; 110: 1100-1107.
153. Howard BV, Cowan LD, Go O, et al. Adverse effects of diabetes on multiple cardiovascular disease risk factors in women: the Strong Heart Study. Diabetes Care 1998; 21: 1258-1265.
154. Chun BY, Dobson AJ and Heller RF. The impact of diabetes on survival among patients with first myocardial infarction. Diabetes Care 1997; 20: 704-708.
155. Kuusisto J, Mykkanen L, Pyorala K and Laakso M. NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 1994; 43: 960-967.
156. Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 1995; 18: 258-268.
157. Alberti G, Mazze R, eds. Frontiers in Diabetes Research: Current Trends in Non-Insulin Dependent Diabetes Mellitus. Amsterdam: Excerta Medica, 1989.
158. Wei M, Gaskill SP, Haffner SM and Stern MP. Effects of diabetes and level of glycemia on allcause and cardiovascular mortality. The San Antonio Heart Study. Diabetes Care 1998; 21(7): 1168-1172.
159. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 838-853.
160. Orchard TJ, Dorman JS, Maser RE, et al. Factors associated with avoidance of severe complications after 25 yr of IDDM: Pittsburgh Epidemiology of Diabetes Complications Study I. Diabetes Care 1990; 13: 741-747.
161. Neil A, Hawkins M, Potok M, et al. A prospective population-based study of microalbuminuria as a predictor of mortality in NIDDM. Diabetes Care 1993; 16: 996-1003.
162. Dandona P. Endothelium, inflammation and diabetes. Curr Diab Rep 2002; 2: 311-315.
163. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347: 1557-1565.
164. Kinlay S and Selwyn AP. Effects of statins on inflammation in patients with acute and chronic coronary syndromes. Am J Card 2003; 91: 9B-13B.
165. Gaede P, Vedel P, Larsen N, Jensen G, Parving HH and Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-393.
166. He J and Whelton PK. Epidemiology and prevention of hypertension. Med Clin North Am 1997; 81: 1078-1097.
167. Gohdes D, Kaufman S and Valway S. Diabetes in American Indians: an overview. Diabetes Care 1993; 16: 239-243.
168. Flack JM, Ferdinand KC and Nasser SA. Epidemiology of hypertension and cardiovascular disease in African Americans. J Clin Hypertens (Greenwich) 2003; 5 (Suppl 1): 5-11.
169. Ferriss JB. The causes of raised blood pressure in insulin-dependent and non-insulin-dependent diabetes. J Hum Hypertens 1991; 5: 245-254.
170. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J 1998; 317: 703-726.
171. Lewis EJ, Hunsicker LG, Bain RP and Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy: the Collaborative Study Group. N Engl J Med 1993; 329: 1456-1462.
172. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S and Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878.
173. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with type 2 diabetes. N Engl J Med. 2001; 345: 851-860.
174. Mazze RS, Simonson GD, Robinson RL, Kendall DM, Idrogo MA, Adlis SA, Boyce KS, Dunne CJ, Anderson RL and Bergenstal RM. Characterizing blood pressure in individuals with type 2 diabetes: the relationship between clinic selfmonitored blood pressure. Diabet Med 2003; 20: 752-757.
175. Jain A and Krakoff LR. Effect of recorded home blood pressure measurements on the staging of hypertensive patients. Blood Press Monit 2002; 7: 157-161.
176. Masding MG, Jones JR, Bartley E and Sandeman DD. Assessment of blood pressure in patients with Type 2 diabetes: comparison between home blood pressure monitoring, clinic blood pressure measurement and 24-h ambulatory blood pressure monitoring. Diabet Med 2001; 8: 431-437.
177. Mion Jr D, Pierin AMG, Lima JC, et al. Home blood pressure correlates better with left ventricular mass index than clinic and ambulatory blood pressure measurement. 19th Scientific Meeting of the International Society of Hypertension, 2002, Prague.
178. Lou LM, Gimeno JA, Gomez Sanchez R, et al. Comparison of clinical arterial blood pressure, home-arterial blood pressure measurement and ambulatory arterial pressure monitoring in patients with type II diabetes mellitus and diabetic nephropathy. Nefrologia 2002; 22(2): 179-189.
179. Suzuki H, Nakamoto H, Okada H, Sugahara S and Kanno Y. Self-measured systolic blood pressure in the morning is a strong indicator of decline of renal function in hypertensive patients with non-diabetic chronic renal insufficiency. Clin Exp Hypertens 2002; 24(4): 249-260.
180. ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
181. NCEP Expert Panel. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). National Institutes of Health Pub. No. 01-3670, 2001.
182. Colwell JA. Aspirin therapy in diabetes. Diabetes Care 1997; 20: 1768-1771.
183. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333.
184. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6-8 years of hormone therapy: Heart and Estrogen/Progestin Replacement Study follow-up (HERS II). JAMA 2002; 288: 49-57.
185. Stampfer MJ, Malinow MR, Willett WC, et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992; 268: 878-881.
186. Friedberg CE, Janssen MJ, Heine RJ and Grobbee DE. Fish oil and glycemic control in diabetes: a meta-analysis. Diabetes Care 1998; 21: 494-500.
187. AHA Scientific Statement: Fish Consumption, Fish Oil, Omega-3 Fatty Acids and Cardiovascular Disease, 71-0241 Circulation 2002; 106: 2747-2757.
188. Gabay C and Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340: 448-454.
189. Heinecke JW. Clinical trials of vitamin E in coronary artery disease: is it time to reconsider the low-density lipoprotein oxidation hypothesis. Curr Atheroscler Rep 2003; 5: 83-87.
190. Jerums G, Allen TJ, Gilbert R, et al. Natural history of diabetic
191. Coonrod BA, Ellis D, Becker DJ, et al. Predictors of microalbuminuria in individuals with IDDM. Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care 1993; 16: 1376-1383.
192. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
193. Raguram P, Massy ZA and Keane WF. Diabetic hyperlipidemia: vascular disease implications and therapeutic options. In: Baba S and Kaneko T, eds. Diabetes 1994. Amsterdam: Elsevier, 1994: 706-712 (Excerpta Medica International Congress Series 1100).
194. Nelson RG, Knowler WC, Pettitt DJ and Bennett PH. Kidney diseases in diabetes. In: Harris MI, Cowie CC, Stern MP, et al., eds. Diabetes in America. 2nd ed. National Diabetes Data Group, NIH, NIDDK, 1995. National Institutes of Health Publication 95-1468.
195. Turtle JR, Yue DK, Fisher EJ, Hefferman SJ, McLennan SV and Zilkens RR. The mesangium in diabetes. In: Baba S and Kaneko T, eds. Diabetes 1994. Amsterdam: Elsevier, 1994: 32-36 (Excerpta Medica International Congress Series 1100).
196. Larkins RG and Dunlop ME. The link between hyperglycemia and diabetic nephropathy. Diabetologia 1992; 35: 499-504.
197. Nelson RG, Knowler WC, Pettitt DJ, Hanson RL and Bennett PH. Incidence and determinants of elevated urinary albumin excretion in Pima Indians with NIDDM. Diabetes Care 1995; 18: 182-187.
198. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
199. Mathiesen ER, Ronn B, Jensen T, Storm B and Deckert T. Relationship between blood pressure and urinary albumin excretion in development of microalbuminuria. Diabetes 1990; 39: 245-249.
200. Microalbuminuria Collaborative Study Group. Microalbuminuria in type 1 diabetic patients. Diabetes Care 1992; 15: 495-501.
201. American Diabetes Association. Clinical Practice Recommendations 2003. Diabetic Nephropathy. Diabetes Care 2003; 26(suppl 1): S94-S98.
202. Burtis CA and Ashwood ER eds. Tietz Textbook of Clinical Chemistry. 2nd ed. Philadelphia, PA: Saunders, 1994: 989-990 and 1522-1538.
203. U.S. Renal Data System. USRDS 2002 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2002.
204. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S and Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878.
205. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with type 2 diabetes. N Engl J Med 2001; 345: 851-860.
206. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z and Shahinfar S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345: 861-869.
207. ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
208. Klein R, Klein B, Moss SE and Cruickshanks KJ. Relationship of hyperglycemia to the long-term incidence and progression of diabetic retinopathy. Arch Intern Med 1994; 154: 2169-2178.
209. Klein R and Klein BE. Vision disorders in diabetes. In: Harris MI, Cowie CC, Stern MP, et al., eds. Diabetes in America. 2nd ed. National Diabetes Data Group, NIH, NIDDK, 1995; National Institute of Health Publication 95-1468.
210. Santiago JV, ed. Medical Management of Insulin-Dependent (Type I) Diabetes. 2nd ed. Alexandria, VA: American Diabetes Association, 1994.
211. Lyons TJ, Silvestri G, Dunn JA, Dyer DG and Baynes JW. Role of glycation in modification of lens crystallins in diabetic and nondiabetic senile cataracts. Diabetes 1991; 40: 1010-1015.
212. Ansari N, Awasthi Y and Srirastava S. Role of glycosylation in protein disulfide formation and cataractogenesis. Exp Eye Res 1980; 31: 9-19.
213. Frank RN. The aldose reductase controversy. Diabetes 1994; 43: 169-172.
214. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
215. The Kroc Collaborative Study Group. Blood glucose control and the evolution of diabetic retinopathy and albuminuria. A preliminary multicenter trial. N Engl J Med 1984; 311: 365-372.
216. The Kroc Collaborative Study Group. Diabetic retinopathy after two years of intensified insulin treatment. Follow-up of The Kroc Collaborative Study. JAMA 1988; 260: 37-41.
217. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
218. Klein R, Klein B, Moss SE, Davis MD and DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 1984; 102: 527-532.
219. ETDRS Research Group. Photocoagulation for diabetic macular edema. Arch Ophthalmol 1985; 103: 1796-1806.
220. Diabetic Retinopathy Vitrectomy Study Research Group. Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision: results of a randomized trial-Diabetic Retinopathy Vitrectomy Study Report 3. Arch Ophthalmol 1988; 95: 1307-1320.
221. Diabetic Retinopathy Vitrectomy Study Research Group. Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy: four-year results of a randomized trial-Diabetic Retinopathy Study Report 5. Arch Ophthalmol 1990; 108: 959-964.
222. UK Prospective Diabetes Study Group. Tight blood pressure control and risk for of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 708-713.
223. Estacio RO, Jeffers BW, Gifford N, Schreir RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000; 23: B54-B64.
224. American Diabetes Association. Clinical Practice Recommendations 2003. Diabetic retinopathy. Diabetes Care 2003; 26(suppl 1): S99-S102.
225. Eastman RC. Neuropathy in diabetes. In: Harris, MI, Cowie CC, Stern MP, et al., eds. Diabetes in America. 2nd ed. National Diabetes Data Group, NIH, NIDDK, 1995; National Institute of Health Publication 95-1468.
226. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
227. Jamal GA. Pathogenesis of diabetic neuropathy: the role of n-6 essential fatty acids and their eicosanoid derivatives. Diabetes Med 1990; 7: 574-579.
228. Boulton AJ and Malik RA. Diabetic neuropathy. Med Clin North Am 1998; 82: 909-929.
229. Raskin P. The relationship of aldose reductase activity to diabetic complications. In: Baba S and Kareko T, eds. Diabetes 1994. Amsterdam: Elsevier, 1994: 321-325 (Excerpta Medica International Congress Series 1100).
230. Max MB, Lynch SA, Muir J, Shoaf SE, Smoller B and Dubner R. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992; 326: 1250-1256.
231. Pfeifer MA. A highly successful and novel model for treatment of chronic painful diabetic peripheral neuropathy. Diabetes Care 1993; 16: 1103-1115.
232. Santiago JV, ed. Medical Management of Insulin-Dependent (Type I) Diabetes. 2nd ed. Alexandria, VA: American Diabetes Association, 1994.
233. Vinik A, Maser R, Mitchell B, Freeman R. Diabetic autonomic neuropathy: Technical review. Diabetes Care 2003; 26: 1553-1579.
234. Erbas T, Varoglu E, Erbas B, Tastekin G and Ahalin S. Comparison of metoclopramide and erythromycin in the treatment of diabetic gastroparesis. Diabetes Care 1993; 16: 1511-1514.
235. Valdovinos MA, Camilleari M and Zimmerman BR. Chronic diarrhea in diabetes mellitus: mechanisms and an approach to diagnosis and treatment. Mayo Clin Proc 1993; 68: 691-702.
236. Fedorak RN, Field M and Chang EB. Treatment of diabetic diarrhea with clonidine. Ann Intern Med 1985; 102: 197-199.
237. Nakabayashi H, Fujii S, Miwa U, Seta T and Takeda R. Marked improvement of diabetic diarrhea with the somatostatin analogue octreotide. Arch Intern Med 1994; 154: 1863-1867.
238. Haines ST. Treating constipation in the patient with diabetes. Diabetes Educ 1995; 21: 223-232.
239. Rith Najarian S, Branchaud C, Beaulieu O, Gohdes D, Simonson G and Mazze R. Reducing lower extremity amputations due to diabetes: application of the Staged Diabetes Management approach in a primary care setting. J Fam Pract 1998; 47: 127-132.
240. Alvarez OM, Gilson G and Auletta MJ. Local aspects of diabetic foot ulcer care: assessment, dressings, topical agents In: Levin ME, ed. The Diabetic Foot. 5th ed. 1993: 259-281.
241. American Diabetes Association. Foot care in patients with diabetes mellitus. Diabetes Care 1998; 21: S54-S55.
242. Caputo GM, Cavanagh, PR, Ulbrecht JS, Gibbons GW and Karchmer AW. Assessment and management of foot disease in patients with diabetes. N Engl J Med 1994; 331: 854-860.
243. Edmonds ME. Improved survival of the diabetic foot: the role of a specialized foot clinic. Q J Med 1986; 232: 763-771.
244. Litzelman DK, Slemenda DW, Langefeld CD, Hays LM, Welch, MA, Bild DE, Ford ES and Vinicor F. Reduction of lower extremity clinical abnormalities in patients with non-insulin dependent diabetes mellitus: a randomized, controlled trial. Ann Intern Med 1993; 119: 36-41.
245. Malone JM, Synder M, Anderson G, et al. Prevention of amputation by diabetic education. Am J Surg 1989; 158: 520-524.
246. McNeely MJ. The independent contributions of diabetic neuropathy and vasculopathy in foot ulceration. Diabetes Care 1995; 18: 216-219.
247. Mitchell BD, Hawthorne VM and Vinik AI. Cigarette smoking and neuropathy in diabetic patients. Diabetes Care 1990; 13: 434-437.
248. Orchard TJ and Strandness DE. Assessment of peripheral vascular disease in diabetes: report and recommendations of an international workshop. Circulation 1993; 88: 819-828.
249. Osmundson PJ. Course of peripheral occlusive arterial disease: vascular laboratory assessment. Diabetes Care, 1990; 13: 143-152.
250. Plummer SE and Albert SG. Foot care assessment in patients with diabetes: a screening algorithm for patient education and referral. Diabetes Educator 1995; 21: 47-51.
251. Rith-Najarian S, Soluski T and Gohdes DM. Identifying patients at high-risk for lower extremity amputation in a primary care setting: a prospective evaluation of simple screening criteria. Diabetes Care 1992; 15: 1386-1389.
252. Rith-Najarian S, Price M and Gohdes DM. Foot care in minorities: preventing amputations in highrisk populations. In: Levin ME, ed. The Diabetic Foot. 5th ed. 1993: 577-586.
253. Rith Najarian S and Gohdes DM. Foot disease in diabetes [Letter]. N Engl J Med 1995; 332: 269-269.
254. Rosenblum BL. Maximizing foot salvage by a combined approach to foot ischemia and neuropathic ulceration in patients with diabetes. Diabetes Care 1994; 17: 983-987.
255. Yosipovitch G, Hodak E and Vardi P. The prevalence of cutaneous manifestations in IDDM patients and their association with diabetes risk factors and microvascular complications. Diabetes Care 1998; 21: 506-509.
256. Jelinek JE. The skin in diabetes. Diabetes Med 1993; 10: 201-213.
257. Arkkila PE, Kantola IM and Viikari JS. Limited joint mobility in type 1 diabetic patients: correlation to other diabetic complications. J Intern Med 1994; 236: 215-223.
258. Arkkila PE, Kantola IM and Viikari JS. Dupuytren's disease: association with chronic diabetic complications. J Rheumatol 1997; 24: 153-159.
259. Loe H. Periodontal disease: the sixth complication of diabetes mellitus. Diabetes Care 1993; 16: 329-34.
260. Grant-Theule DA. Periodontal disease, diabetes, and immune response: a review of current concepts. J West Soc Periodontal Abstr 1996; 44: 69-77.
261. Loe H and Genco RJ. Oral complications in diabetes. In: Diabetes in America. 2nd ed. National Diabetes Data Group, NIH, NIDDK, 1995; National Institutes of Health Publication 95-1468.
262. Aubert RE, Geiss LS, Ballard DJ, Cocanougher B, and Herman WH. Diabetes-related hospitalization and hospital utilization. In: Diabetes in America. 2nd ed. NIH Publication No. 95-1468, 1995.
263. Alberti G. Diabetes emergencies. In Galloway J, Potvin J, Shulman C, eds. Diabetes Mellitus. 9th ed. Indianapolis, In: Lilly, 1988.
264. Alberti G, and Mazze R, eds. Frontiers in Diabetes Research: Current Trends in Non-Insulin Dependent Diabetes Mellitus. Amsterdam: Excerta Medica, 1989.
265. Babineau TJ, and Bothe A. General surgery considerations in the diabetic patient. Infect Dis Clin North Am 1995; 9: 183-193.
266. Bergenstal R, Etzwiler D, Hollander P, Spencer M, Strock E, and Mazze R. In: Alberti G, Mazze R, eds. Frontiers in Diabetes Research: Current Trends in Non-Insulin-Dependent Diabetes Mellitus. Amsterdam: Excerpta Medica, 1989.
267. Cryer PE, Fisher JN, and Shamoon H. Hypoglycemia: technical review. Diabetes Care 1994; 17: 734-755.
268. Fish LH, Weaver TW, Moore AL, and Steel LG. Value of postoperative blood glucose in predicting complications and length of stay after coronary artery bypass grafting. Am J Cardiol. 2003; 92: 74-76.
269. Groop LC. Sulfonylureas in NIDDM. Diabetes Care 1995; 15: 737-754.
270. Hirsch IB, and McGill JB. The role of insulin in the treatment of diabetes mellitus during surgery. Diabetes Care 1990; 13: 980-991.
271. Hirsch IB, Paauw DS, and Brunzell J. Inpatient management of adults with diabetes. Diabetes Care 1995; 18: 870-878.
272. Medical Management of Type 2 Diabetes. 4th ed. Alexandria, VA: American Diabetes Association, 1998.
273. Shulman C. Diabetes mellitus and surgery. In: Galloway J, Potvin J, Shulman C, eds. Diabetes Mellitus. 9th ed. Indianapolis, In: Lilly, 1988.